Peripheral Neuritis Treatment Market Size & Share, by Drug Class (Anti-Depressants, Tricyclic, Selective Serotonin/ Norepinephrine Reuptake Inhibitors); Application (Diabetic, Chemotherapy-Induced, Idiopathic); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4378
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Companies Dominating the Peripheral Neuritis Treatment Market

top-features-companies
    • Eli Lilly and Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott
    • Bristol Myers Squibb Company
    • Novartis AG
    • Pfizer Inc.
    •  GSK Group of Companies
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • RxFunction, Inc.
    • Cipla Limited 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Abbot - launched Proclaim DRG Neurostimulation System, a DRG stimulation therapy. It will involve surgically placing a stimulator that will target the dorsal root ganglion and relieve lower limb pain caused by CRPS.

  • Eli Lilly and Company - is acquiring Disarm Therapeutics, a biotechnology company. Disarm Therapeutics has developed SARM1 inhibitors to deliver treatments for peripheral neuropathy and neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4378
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising chronic diseases globally, and the large aging population are some of the major factors anticipated to drive the growth of the market.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023-2033.

The high cost of peripheral neuritis treatment, stringent government rules and the availability of other diagnosis procedures are some of the factors estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Eli Lilly and Company, Abbott, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GSK Group of Companies, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, RxFunction, Inc., Cipla Limited., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, application, distribution channel, and by region.

The diabetic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying